NOT-NS-22-018: Notice of Change to PAR-22-026 "Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)"

Notice of Change to PAR-22-026 "Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)"

Notice Number:

NOT-NS-22-018

Key Dates

Release Date:

September 1, 2021

Related Announcements

PAR-22-026 - Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this notice is to inform applicants of a correction to the Letter of Intent (LOI) due date for PAR-22-026 "Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)". The LOI is due October 8, 2021; this is 30 days prior to the application due date. Changes to the FOA are shown below.

Currently Reads:

Part 1. Overview Information:

Key Dates:

Letter of Intent Due Date(s)

November 8, 2021

Modified to Read:

Part 1. Overview Information:

Key Dates:

Letter of Intent Due Date(s)

October 8, 2021

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Francesca Bosetti, Pharm.D., Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1431
Email: [email protected]